BR112013011448A2 - composto, composição farnmacêutica, e, uso do composto - Google Patents

composto, composição farnmacêutica, e, uso do composto

Info

Publication number
BR112013011448A2
BR112013011448A2 BR112013011448A BR112013011448A BR112013011448A2 BR 112013011448 A2 BR112013011448 A2 BR 112013011448A2 BR 112013011448 A BR112013011448 A BR 112013011448A BR 112013011448 A BR112013011448 A BR 112013011448A BR 112013011448 A2 BR112013011448 A2 BR 112013011448A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
BR112013011448A
Other languages
English (en)
Other versions
BR112013011448B8 (pt
BR112013011448B1 (pt
Inventor
Anthony Ginnetti
C Blair Zartman
Cheng Wang
Daniel V Paone
Donnette D Staas
Heather E Stevenson
Helen J Mitchell
Ian M Bell
Mark E Fraley
Steven N Gallichio
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of BR112013011448A2 publication Critical patent/BR112013011448A2/pt
Publication of BR112013011448B1 publication Critical patent/BR112013011448B1/pt
Publication of BR112013011448B8 publication Critical patent/BR112013011448B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
BR112013011448A 2010-11-12 2011-11-10 Composto, composição farnmacêutica, e, uso do composto BR112013011448B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41307710P 2010-11-12 2010-11-12
US61/413,007 2010-11-12
US201061425034P 2010-12-20 2010-12-20
US61/425,034 2010-12-20
PCT/US2011/060081 WO2012064910A1 (en) 2010-11-12 2011-11-10 Piperidinone carboxamide azaindane cgrp receptor antagonists

Publications (3)

Publication Number Publication Date
BR112013011448A2 true BR112013011448A2 (pt) 2016-08-09
BR112013011448B1 BR112013011448B1 (pt) 2021-06-01
BR112013011448B8 BR112013011448B8 (pt) 2022-03-29

Family

ID=45034191

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013011448A BR112013011448B8 (pt) 2010-11-12 2011-11-10 Composto, composição farnmacêutica, e, uso do composto

Country Status (42)

Country Link
US (8) US8481556B2 (pt)
EP (2) EP2821407B1 (pt)
JP (1) JP5642883B2 (pt)
KR (1) KR101537877B1 (pt)
CN (1) CN103328478B (pt)
AR (1) AR083831A1 (pt)
AU (1) AU2011326454B2 (pt)
BR (1) BR112013011448B8 (pt)
CA (1) CA2817100C (pt)
CL (1) CL2013001289A1 (pt)
CO (1) CO6801723A2 (pt)
CR (1) CR20130214A (pt)
CY (1) CY1118362T1 (pt)
DK (2) DK2638042T3 (pt)
DO (1) DOP2013000103A (pt)
EA (1) EA022850B1 (pt)
EC (1) ECSP13012676A (pt)
ES (2) ES2604827T3 (pt)
FI (1) FIC20230034I1 (pt)
FR (1) FR23C1039I1 (pt)
GT (1) GT201300122A (pt)
HK (1) HK1200163A1 (pt)
HR (2) HRP20141108T1 (pt)
HU (2) HUE031010T2 (pt)
IL (1) IL225978A (pt)
LT (1) LT2821407T (pt)
MA (1) MA34650B1 (pt)
ME (2) ME02552B (pt)
MX (1) MX2013005246A (pt)
MY (1) MY165113A (pt)
NI (1) NI201300043A (pt)
NL (1) NL301248I2 (pt)
NO (1) NO2023040I1 (pt)
NZ (1) NZ610468A (pt)
PE (1) PE20140240A1 (pt)
PL (2) PL2821407T3 (pt)
PT (2) PT2638042E (pt)
RS (2) RS53610B1 (pt)
SG (2) SG190137A1 (pt)
SI (2) SI2638042T1 (pt)
TW (3) TWI522355B (pt)
WO (1) WO2012064910A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI522355B (zh) * 2010-11-12 2016-02-21 默沙東藥廠 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
EP2685826B1 (en) 2011-03-18 2016-02-03 Merck Sharp & Dohme Corp. Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
US9487523B2 (en) * 2012-03-14 2016-11-08 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
US9174989B2 (en) * 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
KR20210153745A (ko) * 2013-09-16 2021-12-17 머크 샤프 앤드 돔 코포레이션 Cgrp 수용체 길항제를 위한 제제
EP3102564A4 (en) * 2014-02-05 2017-10-18 Merck Sharp & Dohme Corp. Tablet formulation for cgrp-active compounds
FR3030521B1 (fr) * 2014-12-23 2019-07-26 Galderma Research & Development Nouveaux composes heterocycliques et leur utilisation en medecine ainsi qu'en cosmetique
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
GB201908430D0 (en) * 2019-06-12 2019-07-24 Heptares Therapeutics Ltd Cgrp antagonist compounds
CN110787163B (zh) * 2019-12-05 2020-06-02 河北医科大学第二医院 一种用于神经保护和促进神经再生的药物组合物及其制剂
CN112353767A (zh) * 2020-11-16 2021-02-12 海南锦瑞制药有限公司 一种盐酸地尔硫卓和普瑞巴林组合物及其制备方法及其应用
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
EP4301362A1 (en) 2021-03-02 2024-01-10 CGRP Diagnostics GmbH Treatment and/or reduction of occurrence of migraine
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
WO2023119327A1 (en) * 2021-12-20 2023-06-29 Msn Laboratories Private Limited, R&D Center Process for the preparation of a pure amorphous form of ubrogepant
TW202342028A (zh) * 2022-04-29 2023-11-01 大陸商熙源安健醫藥（上海）有限公司 哌啶甲醯胺氮雜茚滿類衍生物及其製備方法和用途
WO2024081718A1 (en) 2022-10-11 2024-04-18 Allergan Pharmaceuticals International Limited Cgrp receptor antagonist for the treatment of migraine

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
WO2004087649A2 (en) 2003-03-14 2004-10-14 Merck & Co., Inc. Benodiazepine spirohydantoin cgrp receptor antagonists
JP4690313B2 (ja) 2003-03-14 2011-06-01 メルク・シャープ・エンド・ドーム・コーポレイション カルボキサミドスピロヒダントインｃｇｒｐ受容体アンタゴニスト
JO2355B1 (en) * 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
EP1797073B1 (en) * 2004-09-13 2010-04-14 Merck Sharp & Dohme Corp. Bicyclic anilide spirolactam cgrp receptor antagonists
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
CA2599925A1 (en) * 2005-03-14 2006-09-21 Merck & Co., Inc. Cgrp receptor antagonists
BRPI0711352A2 (pt) 2006-05-09 2011-09-27 Merck & Co Inc composto, composição farmacêutica, e, métodos para o antagonismo de atividade receptora de cgrp em um mamìfero, e para, tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca , ou cefaléia vascular
WO2008153849A1 (en) * 2007-06-05 2008-12-18 Merck & Co., Inc. Carboxamide heterocyclic cgrp receptor antagonists
EP2225237A2 (de) * 2007-11-22 2010-09-08 Boehringer Ingelheim International GmbH Organische verbindungen
US8044043B2 (en) * 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
US8765763B2 (en) * 2009-06-05 2014-07-01 Boehringer Ingelheim International Gmbh Substituted piperazines as CGRP antagonists
TWI522355B (zh) * 2010-11-12 2016-02-21 默沙東藥廠 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
AU2011326455A1 (en) * 2010-11-12 2013-05-23 Merck Sharp & Dohme Corp. Piperidinone carboxamide indane CGRP receptor antagonists
EP2654423B1 (en) * 2010-12-22 2016-12-07 Merck Sharp & Dohme Corp. Fused heterocyclic azaindane carboxamide cgrp receptor antagonists
US8895572B2 (en) * 2010-12-22 2014-11-25 Merck Sharp & Dohme Corp. Fused heterocyclic indane carboxamide CGRP receptor antagonists
EP2685826B1 (en) * 2011-03-18 2016-02-03 Merck Sharp & Dohme Corp. Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
US9109209B2 (en) * 2011-09-08 2015-08-18 Codexis, Inc. Biocatalysts and methods for the synthesis of substituted lactams
US9487523B2 (en) * 2012-03-14 2016-11-08 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
KR102061180B1 (ko) * 2012-03-14 2019-12-31 머크 샤프 앤드 돔 코포레이션 비대칭 상 이동 촉매로서의 비스-4급 신코나 알칼로이드 염
US9227973B2 (en) * 2012-05-09 2016-01-05 Merck Sharp & Dohme Corp. Pyridine CGRP receptor antagonists
US9227972B2 (en) * 2012-05-09 2016-01-05 Merck Sharp & Dohme Corp. Aliphatic spirolactam CGRP receptor antagonists
WO2013169567A1 (en) * 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Spirolactam cgrp receptor antagonists
US9174989B2 (en) * 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
KR20210153745A (ko) * 2013-09-16 2021-12-17 머크 샤프 앤드 돔 코포레이션 Cgrp 수용체 길항제를 위한 제제
EP3102564A4 (en) * 2014-02-05 2017-10-18 Merck Sharp & Dohme Corp. Tablet formulation for cgrp-active compounds
CN106456662A (zh) * 2014-02-24 2017-02-22 奥利金制药公司 口服给药的戊聚糖多硫酸盐的组合物及其使用方法
US20180092899A1 (en) * 2016-09-30 2018-04-05 Merck Sharp & Dohme Corp. Method of treating acute migraine with cgrp-active compound

Also Published As

Publication number Publication date
KR20130087037A (ko) 2013-08-05
HRP20161641T1 (hr) 2017-01-13
ME02552B (me) 2017-02-20
PL2638042T3 (pl) 2015-03-31
CY1118362T1 (el) 2017-06-28
DK2821407T3 (da) 2017-01-02
EP2821407A1 (en) 2015-01-07
EP2638042B1 (en) 2014-09-24
LT2821407T (lt) 2016-12-12
US20150005330A1 (en) 2015-01-01
FIC20230034I1 (fi) 2023-11-10
NI201300043A (es) 2013-07-01
EA201390683A1 (ru) 2013-09-30
DK2638042T3 (en) 2015-01-05
US20120122899A1 (en) 2012-05-17
EP2638042A1 (en) 2013-09-18
SI2638042T1 (sl) 2015-01-30
TWI501968B (zh) 2015-10-01
CN103328478A (zh) 2013-09-25
US10272077B2 (en) 2019-04-30
CO6801723A2 (es) 2013-11-29
US20210008055A1 (en) 2021-01-14
ME01922B (me) 2015-05-20
AR083831A1 (es) 2013-03-27
RS55416B1 (sr) 2017-04-28
NZ610468A (en) 2015-06-26
US20120122911A1 (en) 2012-05-17
MY165113A (en) 2018-02-28
BR112013011448B8 (pt) 2022-03-29
PT2638042E (pt) 2014-12-09
US8912210B2 (en) 2014-12-16
CL2013001289A1 (es) 2013-08-09
AU2011326454A1 (en) 2013-05-23
TW201305165A (zh) 2013-02-01
SG190137A1 (en) 2013-07-31
ES2604827T3 (es) 2017-03-09
US9499545B2 (en) 2016-11-22
NO2023040I1 (no) 2023-10-20
NL301248I2 (nl) 2023-11-20
IL225978A0 (en) 2013-06-27
TWI522355B (zh) 2016-02-21
TWI487706B (zh) 2015-06-11
PT2821407T (pt) 2016-12-06
EA022850B1 (ru) 2016-03-31
KR101537877B1 (ko) 2015-07-17
DOP2013000103A (es) 2013-10-15
US20120122900A1 (en) 2012-05-17
MX2013005246A (es) 2013-05-28
CN103328478B (zh) 2015-10-07
JP2013542260A (ja) 2013-11-21
US9833448B2 (en) 2017-12-05
MA34650B1 (fr) 2013-11-02
TW201520214A (zh) 2015-06-01
PE20140240A1 (es) 2014-03-14
WO2012064910A1 (en) 2012-05-18
SI2821407T1 (sl) 2016-12-30
TW201520213A (zh) 2015-06-01
EP2821407B1 (en) 2016-09-21
CA2817100C (en) 2015-09-29
US8754096B2 (en) 2014-06-17
US20180092900A1 (en) 2018-04-05
CR20130214A (es) 2013-06-28
ECSP13012676A (es) 2013-08-30
AU2011326454B2 (en) 2015-05-21
JP5642883B2 (ja) 2014-12-17
HK1200163A1 (zh) 2015-07-31
US20170027925A1 (en) 2017-02-02
HUS2300037I1 (hu) 2023-11-28
HRP20141108T1 (hr) 2015-01-16
PL2821407T3 (pl) 2017-04-28
IL225978A (en) 2015-11-30
ES2525021T3 (es) 2014-12-16
CA2817100A1 (en) 2012-05-18
GT201300122A (es) 2015-06-02
US8481556B2 (en) 2013-07-09
FR23C1039I1 (fr) 2023-12-08
SG10201509335VA (en) 2015-12-30
RS53610B1 (en) 2015-04-30
BR112013011448B1 (pt) 2021-06-01
US20190275024A1 (en) 2019-09-12
HUE031010T2 (en) 2017-06-28

Similar Documents

Publication Publication Date Title
BR112013011448A2 (pt) composto, composição farnmacêutica, e, uso do composto
BR112013008259A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112013015397A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112014001255A2 (pt) composto, uso de um composto, combinação, e, composição farmacêutica
BR112014013760A2 (pt) composto, composição farmacêutica e uso de um composto
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BR112012022878A2 (pt) composto, composição farmacêutica, uso do compostos e método de tratamento
BR112015000420A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112013006016A2 (pt) compostos de azabenzotiazol, composições e métodos de uso
BR112014005669A2 (pt) composto, composição farmacêutica e uso de um composto
BRPI1008793A2 (pt) composto, uso de um composto, e, composição farmacêutica
BRPI1016219A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112014029115A2 (pt) composto, composição farmacêutica, e, uso de um composto ou composição
BR112014029530A2 (pt) compostos, composição farmacêutica e uso de um composto
BR112014014547A2 (pt) compostos antagonistas de e-selectina, composições e métodos de uso
BR112014003567A2 (pt) composto, uso de um composto, e, composição farmacêutica
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BR112013010988A2 (pt) composição fluída e uso
BR112013030302A2 (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto e dispositivo
IT1403847B1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
BR112014013177A2 (pt) composto, composição farmacêutica e uso de um composto
BR112014013178A2 (pt) composto, composição farmacêutica e uso de um composto
BR112014016635A2 (pt) composto, composição, e, uso de um composto
BRPI1007186A2 (pt) composto, composição farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.21 NA RPI NO 2541 DE 17/09/2019 POR TER SIDO INDEVIDA.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/11/2011, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2630 DE 01/06/2021 QUANTO A PRIORIDADE UNIONISTA.

B25A Requested transfer of rights approved

Owner name: MERCK SHARP AND DOHME LLC (US)